These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Lincoff AM; Califf RM; Topol EJ J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948 [TBL] [Abstract][Full Text] [Related]
3. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
4. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Bhatt DL; Topol EJ JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650 [TBL] [Abstract][Full Text] [Related]
5. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
6. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Sabatine MS; Jang IK Am J Med; 2000 Aug; 109(3):224-37. PubMed ID: 10974186 [TBL] [Abstract][Full Text] [Related]
7. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Berkowitz SD Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626 [TBL] [Abstract][Full Text] [Related]
8. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
11. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Tcheng JE Am Heart J; 2000 Feb; 139(2 Pt 2):S38-45. PubMed ID: 10650315 [TBL] [Abstract][Full Text] [Related]
12. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495 [TBL] [Abstract][Full Text] [Related]
13. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331 [TBL] [Abstract][Full Text] [Related]
18. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy. Juran NB Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235 [TBL] [Abstract][Full Text] [Related]
19. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use. Pang JT; Fort S; Della Siega A; Cohen EA J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543 [TBL] [Abstract][Full Text] [Related]
20. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]